CA3182134A1 - Pharmaceutical composition for treating fatty liver disease - Google Patents

Pharmaceutical composition for treating fatty liver disease

Info

Publication number
CA3182134A1
CA3182134A1 CA3182134A CA3182134A CA3182134A1 CA 3182134 A1 CA3182134 A1 CA 3182134A1 CA 3182134 A CA3182134 A CA 3182134A CA 3182134 A CA3182134 A CA 3182134A CA 3182134 A1 CA3182134 A1 CA 3182134A1
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
formula
fatty liver
liver disease
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3182134A
Other languages
English (en)
French (fr)
Inventor
Hideo Yukioka
Atsuyuki Shimazaki
Tadateru HAMADA
Naoki Ohyabu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of CA3182134A1 publication Critical patent/CA3182134A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3182134A 2020-05-21 2021-05-20 Pharmaceutical composition for treating fatty liver disease Pending CA3182134A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2020-089196 2020-05-21
JP2020089196 2020-05-21
JP2020-134338 2020-08-07
JP2020134338 2020-08-07
PCT/JP2021/019088 WO2021235508A1 (ja) 2020-05-21 2021-05-20 脂肪性肝疾患の治療用医薬

Publications (1)

Publication Number Publication Date
CA3182134A1 true CA3182134A1 (en) 2021-11-25

Family

ID=78707930

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3182134A Pending CA3182134A1 (en) 2020-05-21 2021-05-20 Pharmaceutical composition for treating fatty liver disease

Country Status (10)

Country Link
US (2) US12521375B2 (https=)
EP (1) EP4154880A4 (https=)
JP (1) JP7820294B2 (https=)
KR (1) KR20230013126A (https=)
CN (1) CN115666558A (https=)
AU (1) AU2021275292A1 (https=)
CA (1) CA3182134A1 (https=)
MX (1) MX2022014553A (https=)
TW (1) TW202207919A (https=)
WO (1) WO2021235508A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2023090411A1 (https=) 2021-11-19 2023-05-25

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548738B2 (en) 2000-12-26 2003-04-15 Research Development Foundation ACC2-knockout mice and uses thereof
EP1356276A4 (en) * 2000-12-26 2005-02-02 Res Dev Foundation ACETYL-COENZYME A CARBOXYLASE 2 AS A TARGET IN THE REGULATION OF BULK FAT, FAT STORAGE, ENERGY HOMEOSTASY AND INSULIN ACTION
WO2009144555A1 (en) * 2008-05-28 2009-12-03 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
EP2947082A1 (en) 2009-11-10 2015-11-25 Pfizer Inc N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS
ES2546465T3 (es) 2010-10-29 2015-09-23 Pfizer Inc Inhibidores de N1/N2-lactama acetil-CoA carboxilasa
RS57157B1 (sr) 2011-11-11 2018-07-31 Gilead Apollo Llc Acc inhibitori i njihove primene
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
JP6205152B2 (ja) 2013-03-25 2017-09-27 サイプレス セミコンダクター コーポレーション シリアル通信システム、受信装置およびシリアル通信方法
EP3670496A3 (en) 2013-10-17 2020-09-30 Shionogi&Co., Ltd. Acc2 inhibitors
JP2016079168A (ja) 2014-10-17 2016-05-16 塩野義製薬株式会社 ９員縮合環誘導体
EA201791258A1 (ru) 2015-01-09 2017-12-29 Джилид Аполло, Ллс Комбинированная терапия с применением ингибитора ацетил-коа-карбоксилазы (acc) для лечения неалкогольной жировой болезни печени
CN109072302B (zh) * 2016-03-30 2024-01-16 基恩菲特公司 非酒精性脂肪性肝炎的非侵入性诊断
CN110799187B (zh) * 2017-06-30 2023-10-03 汇科锦公司 螺内酯化合物

Also Published As

Publication number Publication date
CN115666558A (zh) 2023-01-31
JP7820294B2 (ja) 2026-02-25
WO2021235508A1 (ja) 2021-11-25
MX2022014553A (es) 2022-12-15
US20260091022A1 (en) 2026-04-02
EP4154880A4 (en) 2024-06-05
KR20230013126A (ko) 2023-01-26
EP4154880A1 (en) 2023-03-29
AU2021275292A1 (en) 2022-12-15
TW202207919A (zh) 2022-03-01
JPWO2021235508A1 (https=) 2021-11-25
US20230210822A1 (en) 2023-07-06
US12521375B2 (en) 2026-01-13

Similar Documents

Publication Publication Date Title
ES3012663T3 (en) Glp-1r receptor agonist compound and use thereof
JP7224086B2 (ja) Ｍｇａｔ２阻害活性を有する縮合環誘導体
RU2734261C2 (ru) Необязательно конденсированные гетероциклилзамещенные производные пиримидина, пригодные для лечения воспалительных, метаболических, онкологических и аутоиммунных заболеваний
CN106117193A (zh) 新的杂环衍生物及其在神经性疾病治疗中的应用
RU2720488C2 (ru) Замещенные амино шестичленные насыщенные гетероалициклы в качестве ингибиторов dpp-iv длительного действия
CN108689942A (zh) 含氮双环化合物及其制备方法和用途
BR122023011445B1 (pt) Inibidores de autotaxina e usos dos mesmos
US20260091022A1 (en) Pharmaceutical composition for treating fatty liver disease
US20260098031A1 (en) Monocyclic compound having glp-1 receptor agonist activity
BR112020014320A2 (pt) Derivados de oxadiazolopiridina substituída por heterociclila para uso como inibidores de grelina o-acil transferase (goat)
JP2020111571A (ja) Ｍｇａｔ２阻害活性を有する縮合環誘導体を含有する医薬組成物
JP2021512075A (ja) 一過性受容体電位ａ１イオンチャネルの阻害
BR112021012428A2 (pt) Derivado de dihidropirazolopirazinona tendo atividade inibitória de mgat2
US20250041279A1 (en) Therapeutic medicine for heart disease or skeletal muscle disease
WO2017110841A1 (ja) Ｍｇａｔ２阻害活性を有する非芳香族複素環誘導体
HK40082231A (en) Pharmaceutical for treating fatty liver diseases
CN104788423B (zh) 一种新的囊性纤维化跨膜传导调节因子抑制剂
TW202233605A (zh) 雙環嗒𠯤酮及其使用方法
US10689394B2 (en) Thieno[2,3-b]pyridine derivative, quinoline derivative, and use thereof
RU2800292C2 (ru) Химические соединения
WO2025108406A1 (zh) 一种靶向降解雄激素受体的双功能嵌合体的杂环化合物及其用途
BR112020006456A2 (pt) compostos químicos
EA041240B1 (ru) Ингибиторы ионного канала a1 с транзиторным рецепторным потенциалом
BR112017025420B1 (pt) Uso de inibidores de autotaxina

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251106

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260204